Small Molecules

26 Mar 2019 Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
26 Mar 2019 Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
26 Mar 2019 Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients
25 Mar 2019 Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress
25 Mar 2019 Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC™ Protein Degrader, ARV-110
25 Mar 2019 Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
25 Mar 2019 PharmaMar announces positive results in its lurbinectedin monotherapy trial for small cell lung cancer
25 Mar 2019 Forxiga approved in Europe for type-1 diabetes
24 Mar 2019 Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study
24 Mar 2019 FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
22 Mar 2019 Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
21 Mar 2019 DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis
21 Mar 2019 Kaleido Biosciences Announces Initiation of Dosing in Non-IND Clinical Studies in Patients with Urea Cycle Disorders and Cirrhosis
21 Mar 2019 Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
21 Mar 2019 Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial
21 Mar 2019 Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis
20 Mar 2019 Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome
20 Mar 2019 Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
20 Mar 2019 Moleculin Announces First Patients Enrolled in Lymphoma Clinical Trial
20 Mar 2019 Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
20 Mar 2019 AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program
20 Mar 2019 Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
20 Mar 2019 Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
19 Mar 2019 NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study
19 Mar 2019 Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up